Stock News

Is Buying Atossa Genetics Inc (NASDAQ:ATOS) Here Good Idea?

Atossa Genetics Inc. (NASDAQ:ATOS) Logo

The stock of Atossa Genetics Inc (NASDAQ:ATOS) registered an increase of 6.66% in short interest. ATOS’s total short interest was 333,000 shares in November as published by FINRA. Its up 6.66% from 312,200 shares, reported previously. With 213,200 shares average volume, it will take short sellers 2 days to cover their ATOS’s short positions. The short interest to Atossa Genetics Inc’s float is 7.08%.

The stock decreased 4.51% or $0.06 during the last trading session, reaching $1.27. About 88,831 shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 80.56% since November 10, 2017 and is downtrending. It has underperformed by 96.18% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $6.99 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Another recent and important Atossa Genetics Inc. (NASDAQ:ATOS) news was published by which published an article titled: “European shares march towards 2-year lows as earnings, politics weigh” on October 23, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *